189 related articles for article (PubMed ID: 23661607)
1. Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Hou X; Li Z; Huang W; Li J; Staiger C; Kuang S; Ratliff T; Liu X
Prostate; 2013 Sep; 73(12):1352-63. PubMed ID: 23661607
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.
Zhang Z; Chen L; Wang H; Ahmad N; Liu X
Cell Cycle; 2015; 14(13):2142-8. PubMed ID: 25927139
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase.
Li H; Liu XS; Yang X; Song B; Wang Y; Liu X
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14633-8. PubMed ID: 20679239
[TBL] [Abstract][Full Text] [Related]
4. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
[TBL] [Abstract][Full Text] [Related]
5. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting Polo-Like Kinase 1 and the Wnt/β-Catenin Signaling Pathway in Castration-Resistant Prostate Cancer.
Li J; Karki A; Hodges KB; Ahmad N; Zoubeidi A; Strebhardt K; Ratliff TL; Konieczny SF; Liu X
Mol Cell Biol; 2015 Dec; 35(24):4185-98. PubMed ID: 26438599
[TBL] [Abstract][Full Text] [Related]
7. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Insights into the Selective Dual BET and PLK1 Inhibitory Activity of a Novel Benzamide Compound in Castration-Resistant Prostrate Cancer.
Akawa OB; Subair TI; Omolabi KF; Okunlola FO; Soliman MES
Chem Biodivers; 2021 Dec; 18(12):e2100519. PubMed ID: 34729902
[TBL] [Abstract][Full Text] [Related]
9. Preferential Killing of Tetraploid Colon Cancer Cells by Targeting the Mitotic Kinase PLK1.
Jemaà M; Kifagi C; Serrano SS; Massoumi R
Cell Physiol Biochem; 2020 Apr; 54(2):303-320. PubMed ID: 32259417
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase1 is required for recruitment of dynein to kinetochores during mitosis.
Bader JR; Kasuboski JM; Winding M; Vaughan PS; Hinchcliffe EH; Vaughan KT
J Biol Chem; 2011 Jun; 286(23):20769-77. PubMed ID: 21507953
[TBL] [Abstract][Full Text] [Related]
11. Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis.
Deeraksa A; Pan J; Sha Y; Liu XD; Eissa NT; Lin SH; Yu-Lee LY
Oncogene; 2013 Jun; 32(24):2973-83. PubMed ID: 22890325
[TBL] [Abstract][Full Text] [Related]
12. Drugging Plk1: An attractive approach to inhibit androgen receptor signaling.
Strebhardt K
Cell Cycle; 2015; 14(14):2193-4. PubMed ID: 26030710
[No Abstract] [Full Text] [Related]
13. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.
Darshan MS; Loftus MS; Thadani-Mulero M; Levy BP; Escuin D; Zhou XK; Gjyrezi A; Chanel-Vos C; Shen R; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
Cancer Res; 2011 Sep; 71(18):6019-29. PubMed ID: 21799031
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments.
Li H; Liu XS; Yang X; Wang Y; Wang Y; Turner JR; Liu X
EMBO J; 2010 Sep; 29(17):2953-65. PubMed ID: 20664522
[TBL] [Abstract][Full Text] [Related]
15. Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality.
Xu Y; Wang Q; Xiao K; Liu Z; Zhao L; Song X; Hu X; Feng Z; Gao T; Zuo W; Zeng J; Wang N; Yu L
Mol Cancer Ther; 2020 Jun; 19(6):1221-1231. PubMed ID: 32220972
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Shao C; Ahmad N; Hodges K; Kuang S; Ratliff T; Liu X
J Biol Chem; 2015 Jan; 290(4):2024-33. PubMed ID: 25505174
[TBL] [Abstract][Full Text] [Related]
17. Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
Cristóbal I; Rojo F; Madoz-Gúrpide J; García-Foncillas J
Mol Cell Biol; 2016 Jun; 36(12):1734-9. PubMed ID: 27090640
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of polo-like kinase 1 suppresses microtubule dynamics in MCF-7 cells.
Rashid A; Naaz A; Rai A; Chatterji BP; Panda D
Mol Cell Biochem; 2020 Feb; 465(1-2):27-36. PubMed ID: 31782084
[TBL] [Abstract][Full Text] [Related]
19. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
